MATTAWAN, August 21, 2007: MPI Research recently announced two high level appointments within the company. Effective August 1, 2007, David Serota, PhD, DABT, was promoted to the position of Vice President, Toxicology and Pathology and will also serve as a member of the company’s senior management team. On the same date, Tina Rogers, PhD, DABT, joined the company as the Associate Director of Research. Both appointments further strengthen the leadership position MPI Research has earned within the Contract Research Organization (CRO) industry.

In his new capacity, Dr. Serota will oversee 60+ Study Directors and serve as the Senior Principal Study Director on several critical ongoing testing programs. With over 31 years of experience as a toxicologist, Dr. Serota is a recognized authority. He has previously served as the Director of Toxicology at Southern Research Institute and as Director of Laboratory Operations at Hazleton Laboratories Vienna (now Covance). Most recently, Dr. Serota was the Executive Director of Toxicology and Senior Study Director at MPI Research. He received his PhD from the University of Tennessee in toxicology and currently serves as a Councilor for the American College of Toxicology. A renowned expert in his field, Dr. Serota will be speaking about CRO/Sponsor relationships at the AusBiotech 2007 National Conference in Australia.

“Dr. Serota’s experience and innovation have set a performance precedent at MPI Research. He has played a key role in our capacity expansion projects, which have allowed us to provide our Sponsors with the timely study starts they need to keep their projects moving forward. In fact, our Sponsors often actively seek his expertise,” said Jim Laveglia, PhD, Executive Vice President and Director of Research at MPI Research. “With Dr. Serota leading our toxicology and pathology efforts, our Sponsors can look forward to continued service enhancements and operational excellence.”

Dr. Rogers brings a unique combination of scientific and business experience to MPI Research. As the Associate Director of Research, she willlead initiatives to enhance the Targeted Discovery Research offerings at the company. Biotherapeutics, including viral and other gene vectors as well as cell therapy, will be an identified area of focus. She will also concentrate on advancing specialized services and capabilities in other key areas of the company. With over 15 years of experience in the CRO industry, she has held key leadership positions, most recently as Vice President of Drug Development at Southern Research Institute. Dr. Rogers received her PhD from the Medical University of South Carolina in molecular and cellular biology and pathobiology, and completed postdoctoral fellowships at Harvard Medical School and Tufts University School of Medicine. She currently serves on the MBA Advisory Board at the Auburn University School of Business (where she received an MBA) and is a member of the Gerson Lehman Group Healthcare Council.

“Dr. Rogers is a knowledgeable leader with proven business acumen,” said Dr. Laveglia. “Her unique combination of credentials and experience will only further strengthen our research team and efforts to provide Sponsors with timely, top-quality, and cost-effective preclinical drug development services.”

MPI Research, with headquarters in Mattawan, Michigan, is one of the worlds leading providers of comprehensive preclinical research and development services. More information on the company’s services can be obtained through the website at www.mpiresearch.com.

Home | News